La vendita allo scoperto per Civeo dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Civeo. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Civeo (NYSE:CVEO) Azioni, Report sulle vendite allo scoperto

Civeo

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.

Civeo Corp

WIIM

CVEO

Civeo shares are trading lower after the company reported worse-than-expected Q3 EPS results.

News

Guidance

Civeo Sees FY24 Revenue $675M-$700M, Adjusted EBITDA $83M-$88M, Maintains Capital Expenditures Guidance $30M-$35M

Earnings

Earnings Beats

Earnings Misses

Civeo Q3 2024 GAAP EPS $(0.36) Misses $(0.02) Estimate, Sales $176.3M Beat $168.755M Estimate

<ul>
<li>Civeo&nbsp;announced today that its Board of Directors has renewed its share repurchase authorization for the Company to repurchase up to&nbsp;5%&nbsp;of its total common shares outstanding over the next twelve months.</li>
<li>Civeo may repurchase shares through open market repurchases and/or privately negotiated transactions, and intends to fund repurchases through cash on hand and cash generated from operations.</li>
</ul>

Buybacks

Reported Earlier, Civeo Renews Share Repurchase Authorization For Up To 5% Of Outstanding Shares

As of Aug 15, 2024, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Heico Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>)</h3>
<ul>
<li>On Aug. 26 after the NYSE closing, HEICO will release its financial results for the third quarter ended July 31. The company's stock gained around 5% over the past month and has a <a href="https://www.benzinga.com/quote/HEI">52-week high of $242.98</a>.</li>
<li>RSI Value: 71.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>HEI Price Action: Shares of Heico gained 0.8% to close at $236.89 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Civeo Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>)</h3>
<ul>
<li>On Aug. 13, Civeo announced amendment and extension to its credit agreement, upsizing total revolving credit facility capacity from $200 million to $245 million. The company's stock gained around 16% over the past month and <a href="https://www.benzinga.com/quote/CVEO">has a 52-week high</a> of $28.25.</li>
<li>RSI Value: 75.08</li>
<li>CVEO Price Action: Shares of Civeo fell 0.4% to close at $27.65 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)</h3>
<ul>
<li>On Aug. 6, Axon Enterprise reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/AXON">52-week high</a> of $375.95.</li>
<li>RSI Value: 74.75</li>
<li>AXON Price Action: Shares of Axon Enterprise gained 0.4% to close at $370.57 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

AXON

Top 3 Industrials Stocks That May Implode In Q3

Financing

Civeo Corporation Announces Amendment And Extension To Its Credit Agreement, Upsizing Total Revolving Credit Facility Capacity From $200M To $245M

Stifel analyst Stephen Gengaro reiterates Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) with a Buy and raises the price target from $31 to $32.

Price Target

Reiteration

Analyst Ratings

Stifel Reiterates Buy on Civeo, Raises Price Target to $32

For the full year of 2024, Civeo is maintaining its previously provided revenue and Adjusted EBITDA&nbsp;guidance&nbsp;ranges of&nbsp;$625 million&nbsp;to&nbsp;$700 million&nbsp;and&nbsp;$80 million&nbsp;to&nbsp;$90 million, respectively. The Company is also maintaining its full year 2024 capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Civeo Is Maintaining Previously Provided FY24 Revenue Guidance Range Of $625M-$700M Vs. $665.18M Estimate

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.21 by 166.67 percent. This is a 86.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $188.71 million which beat the analyst consensus estimate of $173.70 million by 8.64 percent. This is a 5.52 percent increase over sales of $178.84 million the same period last year.

Civeo Q2 GAAP EPS $0.56 Beats $0.21 Estimate, Sales $188.71M Beat $173.70M Estimate

Fraser brings extensive U.S., Canadian and international executive management experience
Al Schoening to retire after 13-year career at Civeo
Civeo Corporation ("Civeo" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) today announced the appointment of Andrew "Andy" S. Fraser, a dynamic and experienced leader, as President, Canada, effective August 19, 2024. He succeeds Al Schoening, Senior Vice President, Canada, who will retire after serving 13 years at Civeo. Mr. Schoening will work closely with Mr. Fraser to ensure a smooth transition and is expected to remain a consultant for the Company for a period after his retirement.

Management

Civeo Appoints Andrew "Andy" S. Fraser As President, Canada, Effective August 19, 2024

Civeo Corporation Announced The Appointment Of E. Collin Gerry As The New Senior Vice President, Chief Financial Officer And Treasurer, Effective August 1, 2024, Replacing The Interim CEO Barclay Brewer

Peter McCann, SVP at Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>), executed a substantial insider sell on May 1, according to an SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001590584/000159058424000081//Archives/edgar/data/1590584/000159058424000081/0001590584-24-000081-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, McCann sold 5,220 shares of Civeo. The total transaction value is $123,975.
At Wednesday morning, Civeo shares are down by 1.16%, trading at $22.95.
<h3>Discovering Civeo: A Closer Look</h3>
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.
<h3>Civeo: Financial Performance Dissected</h3>
Revenue Growth: Civeo's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 21.48%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Civeo's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.35.
</li>
</ul>
Debt Management: Civeo's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 11.16 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.49, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 3.32, Civeo presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001590584">Check Out The Full List Of Civeo's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Civeo SVP Trades $123K In Company Stock

Stifel analyst Stephen Gengaro maintains Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) with a Buy and raises the price target from $30 to $31.

Stifel Maintains Buy on Civeo, Raises Price Target to $31

Shares of Clever Leaves Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLVR#NASDAQ">CLVR</a>) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations.
Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Deciphera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.</li>
<li>Collective Audience, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAUD#NASDAQ">CAUD</a>) gained 50.4% to $0.6002 after the company announced a strategic partnership with Insticator.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares gained 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.</li>
<li>Koninklijke Philips N.V.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares climbed 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) gained 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 25% to $3.9414 after the company announced the California Air Resources Board has approved the 2024 Mullen THREE for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) climbed 25% to $1.7990.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) rose 23.9% to $6.06 after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer&#8217;s Disease.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 23.8% to $2.25. HWH International recently announced that it entered into a joint venture to build its travel business in Asia.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) jumped 22% to $0.2948.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 20.7% to $7.53.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 19% to $1.0250.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) rose 17.8% to $0.7403.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) gained 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.</li>
<li>Heartland Financial USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NASDAQ">HTLF</a>) gained 17.2% to $41.86 after UMB Financial announced it will acquire the company.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) rose 14.6% to $50.08.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) climbed 14.3% to $4.4350. Shares of lithium stocks traded higher, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) gained 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.</li>
<li>Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) rose 11.2% to $4.9182 on FDA clearance of its IND application for PM359.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 10.5% to $185.94 on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) rose 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.</li>
<li>Fulton Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) jumped 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.</li>
<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) gained 8.2% to $1.3850.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Annovis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NASDAQ">ANVS</a>) dipped 57% to $7.72 after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer&#8217;s. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) fell 48.8% to $8.25 after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) shares declined 30.3% to $1.6101 after dipping around 78% on Friday.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 21.8% to $4.8440 after the company announced the exercise of warrants for $4.4 million in gross proceeds.</li>
<li>China Jo-Jo Drugstores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJJD#NASDAQ">CJJD</a>) dipped 21% to $2.29 after the company announced a $1.53 million registered direct offering.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) fell 19.5% to $0.56 after the company said the unaudited financial statements for the quarterly periods ended March 31, 2023, June 30, 2023 and Sept 30, 2023 should no longer be relied on.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) fell 19% to $0.1399. iSun, last week, announced rescission of reverse stock split.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares fell 18.8% to $4.10 after tumbling 70% on Friday.</li>
<li>Top KingWin Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCJH#NASDAQ">TCJH</a>) fell 18% to $0.7301.</li>
<li>STRATA Skin Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) dipped 17.3% to $0.43. The company announced a 1-for-10 reverse stock split.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) fell 16.5% to $6.68.</li>
<li>Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) declined 15.6% to $1.1492.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) fell 15.3% to $7.00.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) shares fell 13.5% to $1.41 after jumping 34% on Friday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 10.4% to $3.0550. Wedbush analyst Alicia Reese reiterated AMC with a Neutral and maintained a $4 price target.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined 10.1% to $1.3493 after declining over 5% on Friday.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) fell 9.9% to $7.09 following first-quarter results.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) dipped 9.7% to $9.90 after the company reported worse-than-expected first-quarter financial results and signed a definitive merger with Territorial Bancorp.</li>
<li>Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares declined 9.3% to $21.55 after the company missed first-quarter EPS and sales estimates.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) fell 9.1% to $16.16 after the company disclosed it estimates it could have to pay up to €1.3 billion related to its Postbank litigation.</li>
<li>Altimmune, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell 9.4% to $6.58 after Guggenheim downgraded the stock from Buy to Neutral.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) fell 8.6% to $17.68.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) declined 8% to $2.7050.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 7.5% to $14.31.</li>
<li>Civeo Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) fell 7% to $23.25.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38491128/nxp-semiconductors-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-ear">NXP Semiconductors Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Intraday Update

Movers

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CGEM

CJJD

CLVR

CSSE

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PAHC

PRME

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

For the full year of 2024, Civeo is maintaining its previously provided Adjusted EBITDA&nbsp;guidance&nbsp;range&nbsp;of&nbsp;$80 million&nbsp;to&nbsp;$90 million and capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Civeo Maintains FY24 Revenue Guidance Range Of $625M-$700M, Est $653.562M

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. The company reported quarterly sales of $166.120 million which beat the analyst consensus estimate of $154.726 million by 7.36 percent. This is a 0.88 percent decrease over sales of $167.591 million the same period last year.

Civeo Q1 2024 GAAP EPS $(0.35) Misses $(0.20) Estimate, Sales $166.120M Beat $154.726M Estimate

Civeo Expects FY24 Revenues Of $625M-$700M Vs. 623.11M Estimate, Sees Adjusted EBITDA Of $80M-$90M And Capital Expenditures Of $30M-$35M

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly sales of $170.80 million which beat the analyst consensus estimate of $151.12 million by 13.02 percent. This is a 5.31 percent increase over sales of $162.19 million the same period last year.

Civeo Q4 Sales $170.80M Beat $151.12M Estimate, Company Exits Q4 With Cash And Equivalents Worth $3.32M

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
Analysts estimate that Civeo will report an earnings per share (EPS) of $0.07. 
Civeo bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.40, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Civeo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.31</td>
<td>-0.26</td>
<td>-0.61</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.61</td>
<td>0.30</td>
<td>-0.42</td>
<td>-0.90</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>1.0%</td>
<td>5.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709139708_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Civeo were trading at $22.32 as of February 27. Over the last 52-week period, shares are down 3.41%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CVEO/earnings">To track all earnings releases for Civeo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Civeo

As the day concludes, Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) is preparing to distribute a dividend payout of $0.24 per share, resulting in an annualized dividend yield of 2.82%. This payout is exclusive to investors who held the stock before the ex-dividend date on February 02, 2024.
<h3>Matthews International Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-02</td>
<td style="text-align: right;">4</td>
<td>$0.24</td>
<td>2.82%</td>
<td>2024-01-24</td>
<td>2024-02-05</td>
<td>2024-02-19</td>
</tr>
<tr>
<td>2023-11-24</td>
<td style="text-align: right;">4</td>
<td>$0.24</td>
<td>2.46%</td>
<td>2023-11-15</td>
<td>2023-11-27</td>
<td>2023-12-11</td>
</tr>
<tr>
<td>2023-08-04</td>
<td style="text-align: right;">4</td>
<td>$0.23</td>
<td>1.92%</td>
<td>2023-07-26</td>
<td>2023-08-07</td>
<td>2023-08-21</td>
</tr>
<tr>
<td>2023-05-05</td>
<td style="text-align: right;">4</td>
<td>$0.23</td>
<td>2.54%</td>
<td>2023-04-26</td>
<td>2023-05-08</td>
<td>2023-05-22</td>
</tr>
<tr>
<td>2023-02-03</td>
<td style="text-align: right;">4</td>
<td>$0.23</td>
<td>2.54%</td>
<td>2023-01-25</td>
<td>2023-02-06</td>
<td>2023-02-20</td>
</tr>
<tr>
<td>2022-11-25</td>
<td style="text-align: right;">4</td>
<td>$0.23</td>
<td>3.3%</td>
<td>2022-11-16</td>
<td>2022-11-28</td>
<td>2022-12-12</td>
</tr>
<tr>
<td>2022-08-05</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>3.27%</td>
<td>2022-07-27</td>
<td>2022-08-08</td>
<td>2022-08-22</td>
</tr>
<tr>
<td>2022-05-06</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>2.97%</td>
<td>2022-04-28</td>
<td>2022-05-09</td>
<td>2022-05-23</td>
</tr>
<tr>
<td>2022-02-04</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>2.59%</td>
<td>2022-01-27</td>
<td>2022-02-07</td>
<td>2022-02-21</td>
</tr>
<tr>
<td>2021-11-26</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>2.28%</td>
<td>2021-11-17</td>
<td>2021-11-29</td>
<td>2021-12-13</td>
</tr>
<tr>
<td>2021-08-06</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>2.55%</td>
<td>2021-07-28</td>
<td>2021-08-09</td>
<td>2021-08-23</td>
</tr>
<tr>
<td>2021-05-07</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>1.99%</td>
<td>2021-04-28</td>
<td>2021-05-10</td>
<td>2021-05-24</td>
</tr>
</tbody>
</table>
With a dividend yield that places it neither at the top nor the bottom, Matthews International finds itself in the middle among its industry peers, while Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) boasts the highest annualized dividend yield at 4.42%.
<h3>Analyzing Matthews International Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708355110_0.png" alt="dividend chart graph" />
From 2020 to 2023, the company's dividend per share showed a positive trend, increasing steadily from $0.84 in 2020 to $0.93 in 2023. This demonstrates the company's commitment to rewarding shareholders by consistently raising dividends.
<h3>YoY Earnings Growth For Matthews International</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708355110_1.png" alt="earning chart graph" />
From 2020 to 2023, Matthews International experienced a decrease in earnings per share, dropping from $3.01 to $2.88. This declining earnings trend may be worrisome for income-seeking investors, as it indicates a potential impact on the company's ability to sustain or increase its cash dividend payouts. Further analysis is necessary to understand the underlying reasons for this decrease.
<h3>Recap</h3>
This article provides an in-depth analysis of Matthews International's recent dividend distribution and the impact it has on shareholders. The company is currently distributing a dividend of $0.24 per share, resulting in an annualized dividend yield of 2.82%.
With a dividend yield that places it neither at the top nor the bottom, Matthews International finds itself in the middle among its industry peers, while Civeo boasts the highest annualized dividend yield at 4.42%.
The rising dividend per share and declining earnings per share of Matthews International from 2020 to 2023 indicate a deliberate choice to prioritize dividend distribution over earnings performance.
Investors should closely follow the company's performance in the coming quarters to stay up-to-date on any shifts in financials or dividend disbursements.
[See current stock movements Matthews International on Benzinga.](https://www.benzinga.com/quote/Matthews International (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/matw#NASDAQ">MATW</a>))
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Small Cap

MATW

Matthews International Continues Support to Investors while Adjusting Profits, Adapting to Market Pressures

Civeo Corporation: Incredibly Cheap Even After Its Recent Rally

Civeo board renews share repurchase authorization

28 Top rated U.S. growth stocks month-to-date in anticipation of Fed cuts

Civeo Corporation Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Civeo Corporation GAAP EPS of -$0.36 misses by $0.34, revenue of $176.34M beats by $7.59M

Civeo Corporation (CVEO) Q3 2024 Earnings Call Transcript

Civeo Corp. ( ($CVEO) ) has realeased its Q3 earnings. Here is a breakdown of the information Civeo Corp. presented to its investors. Civeo Corpora...

Civeo Corp. Reports Q3 2024 Earnings Highlights

Civeo Corporation declares $0.25 dividend

Civeo Corporation: Some Favorable Narratives, But A Challenging Q4 Beckons

AFRM

AQST

ARIS

ARVN

AXTA

BASFY

BIIB

BLKB

BPMC

CHEF

COCO

CRMD

CRTO

CWEN

EADSF

ENIC

EPRT

EXAS

EXTR

FLEX

FVRR

GEHC

GRMN

HESM

IBKR

INMD

INTA

ITCI

IVPAF

KVUE

LKNCY

LWAY

NAVI

NBIX

NECB

NVCR

OMCL

OPCH

OTIS

PLOW

POWL

PUMP

ROCK

SKYW

SPYG

TILE

TMUS

TOST

TTWO

VICI

VOOG

Press Releases

Civeo Announces First Quarter 2024 Earnings Conference Call

Civeo Reports First Quarter 2024 Results

Civeo Appoints E. Collin Gerry as Chief Financial Officer

Civeo Appoints Andrew S. Fraser as President, Canada

Civeo Announces Second Quarter 2024 Earnings Conference Call

Civeo Reports Second Quarter 2024 Results

Civeo Corporation Announces Amendment and Extension to its Credit Agreement

Civeo Corporation Announces Renewal of Share Repurchase Authorization

Civeo Announces Third Quarter 2024 Earnings Conference Call

Civeo Reports Third Quarter 2024 Results

ACV Auctions

Bridger Aerospace Group Holdings, Inc. - Common Stock

Bridger Aerospace Gr

Bitcoin Depot Inc. - Class A Common Stock

Bitcoin Depot

Copart

Cintas

Driven Brands Holdings Inc. - Common Stock

Driven Brands Hldgs

Guardforce AI Co., Limited - Ordinary Shares

Guardforce AI Co

Healthcare Services Group, Inc. - Common Stock

Healthcare Services Group

Openlane

Liquidity Services

Matthews International Corporation - Class A Common Stock

Matthews International

Odyssey Marine Exploration, Inc. - Common Stock

Odyssey Marine Explr

Quhuo Limited - American Depository Shares

Quhuo

RB Global

Sentage Holdings Inc. - Class A Ordinary Shares

Sentage Hldgs

UniFirst

Vestis

Comments

Civeo

Vendite allo scoperto

Civeo (NYSE:CVEO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO